Progression Rates of Diabetic Neuropathy in Placebo Patients in an 18-Month Clinical Trial
- 1 May 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 12 (3) , 121-127
- https://doi.org/10.1016/s1056-8727(97)00074-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The Effects of Age and Diabetes Mellitus on Nerve FunctionJournal of the American Geriatrics Society, 1993
- Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve functionJournal of Diabetes and its Complications, 1993
- Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 monthsJournal of Diabetes and its Complications, 1992
- One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathyDiabetes Research and Clinical Practice, 1991
- A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathyDiabetologia, 1990
- Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with SorbinilNew England Journal of Medicine, 1988
- Thermal sensitivity tester. Device for quantitative assessment of thermal sense in diabetic neuropathyDiabetes, 1986
- Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetesMetabolism, 1986
- Autonomic Neural Dysfunction in Recently Diagnosed Diabetic SubjectsDiabetes Care, 1984
- Aldose Reductase Inhibition Improves Nerve Conduction Velocity in Diabetic PatientsNew England Journal of Medicine, 1983